Methods ADQI (Acute Disease Quality Initiative) is an ongoing process that produces
evidence‐based recommendations on the diagnosis, prevention, and management of AKI …

Left ventricular assist devices (LVADs) improve survival in patients with advanced heart
failure. As LVAD use increases, so do the number of patients with LVADs who also have …

Ventricular assist devices (VADs), among which the HeartMate 3 (HM3) is the latest clinically
approved representative, are often the therapy of choice for patients with end‐stage heart …

The use of left ventricular assist devices (LVADs) as a treatment method for heart failure
patients has been steadily increasing; however, pathological studies showed presence of …

While earlier studies reported no relevant effect of the HeartMate 3 (HM3) artificial pulse
(AP) on bulk pump washout, its effect on regions with prolonged residence times remains …

Controlled and repeatable in vitro evaluation of cardiovascular devices using a mock
circulation loop (MCL) is essential prior to in vivo or clinical trials. MCLs often consist of only …

Objective: The hydraulic properties of implantable rotary blood pumps (RBPs) determine
their interaction with the cardiovascular system. A systematic comparison in this regard has …

Objective Mechanical circulatory support has become a standard therapy for adult patients
with end-stage heart failure. For pediatric patients, technologic development lags behind …

Heart failure occurs when the heart cannot pump adequate blood to the body, which afflicts
over 60 million people worldwide. Its treatment options include physiotherapy, medication …

Left ventricular assist devices are associated with thromboembolic events, which are
potentially caused by altered intraventricular flow. Due to patient variability, differences in …